| John G Durham, DPM | |
|
499 E Central Parkwy, Ste 120, Altamonte Springs, FL 32701 | |
| (407) 331-7844 | |
| (407) 478-3595 |
| Full Name | John G Durham |
|---|---|
| Gender | Male |
| Speciality | Podiatry |
| Experience | 41 Years |
| Location | 499 E Central Parkwy, Altamonte Springs, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235103268 | NPI | - | NPPES |
| 390041000 | Medicaid | FL | |
| P00112206 | Other | FL | R/R MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | PO 2241 (Florida) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Adventhealth Orlando | Orlando, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Upperline Healthcare Pc | 4385900653 | 117 |
News Archive
Xybion Corporation announced today that through the creation of a wholly owned Quebec Corporation, Services Informatiques Xybion, it has completed the acquisition of all operating assets of Quebec City based Amadeus Solutions, a leader in the development of enterprise governance, risk, compliance and quality management software solutions, from DECIMAL, a corporate performance management organization headquartered in Montreal.
EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, announced today that it is presenting the comprehensive analysis of a recently completed Phase 2b clinical trial of EVP-6124, a novel, orally bioavailable nicotinic alpha-7 agonist, in schizophrenia at the American College of Neuropsychopharmacology 50th Anniversary Annual Meeting.
In a new paper released today in Nature, BioFrontiers Institute scientists at the University of Colorado Boulder, Tom Cech and Leslie Leinwand, detailed a new target for anti-cancer drug development that is sitting at the ends of our DNA.
IntriCon Corporation, a designer, developer, manufacturer and distributor of body-worn medical and electronics devices, will unveil its Scenic™ DSP amplifier at AudiologyNOW!, the annual convention of the American Academy of Audiology, being held April 14-17, 2010, at the San Diego Convention Center.
Gilead Sciences, Inc. today announced that a Phase 2 clinical trial evaluating tenofovir alafenamide fumarate, an investigational novel prodrug of tenofovir for the treatment of HIV-1 infection, met its primary objective.
› Verified 3 days ago
| Provider Name | Orlando Foot And Ankle Clinic, Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1235559188 PECOS PAC ID: 6709778632 Enrollment ID: O20040326000171 |
News Archive
Xybion Corporation announced today that through the creation of a wholly owned Quebec Corporation, Services Informatiques Xybion, it has completed the acquisition of all operating assets of Quebec City based Amadeus Solutions, a leader in the development of enterprise governance, risk, compliance and quality management software solutions, from DECIMAL, a corporate performance management organization headquartered in Montreal.
EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, announced today that it is presenting the comprehensive analysis of a recently completed Phase 2b clinical trial of EVP-6124, a novel, orally bioavailable nicotinic alpha-7 agonist, in schizophrenia at the American College of Neuropsychopharmacology 50th Anniversary Annual Meeting.
In a new paper released today in Nature, BioFrontiers Institute scientists at the University of Colorado Boulder, Tom Cech and Leslie Leinwand, detailed a new target for anti-cancer drug development that is sitting at the ends of our DNA.
IntriCon Corporation, a designer, developer, manufacturer and distributor of body-worn medical and electronics devices, will unveil its Scenic™ DSP amplifier at AudiologyNOW!, the annual convention of the American Academy of Audiology, being held April 14-17, 2010, at the San Diego Convention Center.
Gilead Sciences, Inc. today announced that a Phase 2 clinical trial evaluating tenofovir alafenamide fumarate, an investigational novel prodrug of tenofovir for the treatment of HIV-1 infection, met its primary objective.
› Verified 3 days ago
| Provider Name | Upperline Healthcare Pc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1538686498 PECOS PAC ID: 4385900653 Enrollment ID: O20201109001904 |
News Archive
Xybion Corporation announced today that through the creation of a wholly owned Quebec Corporation, Services Informatiques Xybion, it has completed the acquisition of all operating assets of Quebec City based Amadeus Solutions, a leader in the development of enterprise governance, risk, compliance and quality management software solutions, from DECIMAL, a corporate performance management organization headquartered in Montreal.
EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, announced today that it is presenting the comprehensive analysis of a recently completed Phase 2b clinical trial of EVP-6124, a novel, orally bioavailable nicotinic alpha-7 agonist, in schizophrenia at the American College of Neuropsychopharmacology 50th Anniversary Annual Meeting.
In a new paper released today in Nature, BioFrontiers Institute scientists at the University of Colorado Boulder, Tom Cech and Leslie Leinwand, detailed a new target for anti-cancer drug development that is sitting at the ends of our DNA.
IntriCon Corporation, a designer, developer, manufacturer and distributor of body-worn medical and electronics devices, will unveil its Scenic™ DSP amplifier at AudiologyNOW!, the annual convention of the American Academy of Audiology, being held April 14-17, 2010, at the San Diego Convention Center.
Gilead Sciences, Inc. today announced that a Phase 2 clinical trial evaluating tenofovir alafenamide fumarate, an investigational novel prodrug of tenofovir for the treatment of HIV-1 infection, met its primary objective.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| John G Durham, DPM 3165 Mccrory Pl, Ste 174, Orlando, FL 32803-3727 Ph: (407) 423-1234 | John G Durham, DPM 499 E Central Parkwy, Ste 120, Altamonte Springs, FL 32701 Ph: (407) 331-7844 |
News Archive
Xybion Corporation announced today that through the creation of a wholly owned Quebec Corporation, Services Informatiques Xybion, it has completed the acquisition of all operating assets of Quebec City based Amadeus Solutions, a leader in the development of enterprise governance, risk, compliance and quality management software solutions, from DECIMAL, a corporate performance management organization headquartered in Montreal.
EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, announced today that it is presenting the comprehensive analysis of a recently completed Phase 2b clinical trial of EVP-6124, a novel, orally bioavailable nicotinic alpha-7 agonist, in schizophrenia at the American College of Neuropsychopharmacology 50th Anniversary Annual Meeting.
In a new paper released today in Nature, BioFrontiers Institute scientists at the University of Colorado Boulder, Tom Cech and Leslie Leinwand, detailed a new target for anti-cancer drug development that is sitting at the ends of our DNA.
IntriCon Corporation, a designer, developer, manufacturer and distributor of body-worn medical and electronics devices, will unveil its Scenic™ DSP amplifier at AudiologyNOW!, the annual convention of the American Academy of Audiology, being held April 14-17, 2010, at the San Diego Convention Center.
Gilead Sciences, Inc. today announced that a Phase 2 clinical trial evaluating tenofovir alafenamide fumarate, an investigational novel prodrug of tenofovir for the treatment of HIV-1 infection, met its primary objective.
› Verified 3 days ago
Crigler Foot & Ankle Center, Llc Podiatrist Medicare: Medicare Enrolled Practice Location: 616 E Altamonte Dr, Suite 205, Altamonte Springs, FL 32701 Phone: 407-331-3668 Fax: 407-331-3700 | |
Hulbert Foot And Ankle, Llc Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 475 Maitland Ave, Altamonte Springs, FL 32701 Phone: 920-216-0011 | |
German Mikheyev, Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 661 E Altamonte Dr Ste 210, Altamonte Springs, FL 32701 Phone: 407-339-7759 Fax: 407-830-0024 | |
Dr. Howard B Finkelstein, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 661 East Altamonte Drive, Foot And Ankle Associates Of Florida Suite 210, Altamonte Springs, FL 32701 Phone: 407-339-7759 Fax: 407-830-0024 | |
Tara Lynette Fussell, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 661 E Altamonte Dr Ste 210, Altamonte Springs, FL 32701 Phone: 407-339-7759 Fax: 407-830-0024 | |
Fpcf Altamonte Springs Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 697 Douglas Ave, Altamonte Springs, FL 32714 Phone: 407-647-2346 Fax: 407-647-5431 |